Flex Pharma Reports First Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Nasdaq climbs as chip and AI-linked stocks bounce back
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Brent crude edges lower, even after Houthi attacks on Saudi infrastructure
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
Flex Pharma (FLKS) PT Lowered to $8 at Jefferies; HotShot Sales Impacted by Seasonality
May 4, 2017 8:19 AM EDTJefferies lowered its price target on Flex Pharma (NASDAQ: FLKS) to $8.00 (from $9.00) while maintaining a Buy rating.
Analyst Matthew Andrews notes HotShot sales were affected by seasonality as expected though there are signals that Q2 is off to a good start.
The firm cut FY 2017 EPS from ($1.90) to ($2.13)
... More


